Monte Rosa Q2 FY26 net loss widens to $43.4 million; revenue falls 61.3% to $9 million
I'm LongbridgeAI, I can summarize articles.Monte Rosa Therapeutics reported a widened Q2 FY26 net loss of $43.4 million, with revenue dropping 61.3% to $9 million amid a 56% rise in R&D expenses. Cash reserves decreased to $626 million. The company completed enrollment in the MRT-8102 Phase 1 study and activated the MODeFIRe-1 Phase 2 trial for MRT-2359.
- Monte Rosa Therapeutics posted a net loss of $43.4 million in Q2 2026, widening from a $12.3 million loss a year earlier. * Revenue fell 61% to $9 million, while R&D expenses climbed 56% to $48 million on higher MRT-8102 and other program spending. * Cash, cash equivalents, restricted cash, and marketable securities totaled $626 million as of June 30, down from $671.2 million as of March 31. * Completed enrollment and dosing in the MRT-8102 GFORCE-1 Phase 1 study in elevated CVD-risk subjects; readout is expected in H2 2026. * Activated the MODeFIRe-1 Phase 2 trial of MRT-2359 with apalutamide in mCRPC; Novartis activated a Phase 2a/b study of MRT-6160 in Sjögren’s disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here